<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930043</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-MGWAS</org_study_id>
    <nct_id>NCT03930043</nct_id>
  </id_info>
  <brief_title>A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma Patients</brief_title>
  <official_title>A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational study on the fecal microbiota in primary/secondary gastrointestinal
      lymphoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observation study is aimed at investigating the gut microbiota alteration in
      gastrointestinal lymphoma (GIL) patients by performing metagenomic shotgun sequencing on GIL
      patients' fecal specimen. Before immuno-chemotherapy, the feces specimen of GIL would be
      collected and stored for further laboratory examination. This study would NOT alter the
      subsequential treatment of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metagenomic Linkage Groups (MLGs)</measure>
    <time_frame>2 years</time_frame>
    <description>A serial of genes in a metagenome that is probably physically linked as a microbial unit.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Gastrointestinal Lymphoma</condition>
  <arm_group>
    <arm_group_label>Health Control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-gastrointestinal Lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Lymphoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Intestinal Lymphoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Metagenomic shotgun sequencing</intervention_name>
    <description>preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen</description>
    <arm_group_label>Gastric Lymphoma</arm_group_label>
    <arm_group_label>Health Control</arm_group_label>
    <arm_group_label>Intestinal Lymphoma</arm_group_label>
    <arm_group_label>Non-gastrointestinal Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The non-Hodgekin lymphoma patients with gastrointestinal involvement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastrointestinal lymphoma with a clarified pathological diagnosis

          -  De novo gastrointestinal lymphoma patients who haven't received chemotherapy

          -  BMI in normal range

        Exclusion Criteria:

          -  Antibiotics or probiotics application within a month

          -  Overweight (BMI≥25) or malnourished (BMI＜18.5) patients

          -  Patients who have been accepted gastrointestinal fistulation

          -  Gastrointestinal patients with inflammatory bowel disease (IBD), colorectal carcinoma
             (CRC) or any other chronic intestinal disease

          -  Patients infected by HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, MD. PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pengpeng Xu, MD. PhD.</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>xpproc@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingci Cai, Master</last_name>
    <phone>86-21-13621999905</phone>
    <email>chinacmc_girl@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao, MD,PhD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>zhao.weili@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Pengpeng Xu, MD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>xpproc@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Deputy Director of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

